Wednesday, September 7, 2011

Bone Cancer Drug Reconsidered by UK's National Health Service

SEPT. 7, 2011 – Japanese drugmaker Takeda won acceptance of its bone cancer drug, Mepact, to be included in the approved formulary of the state-funded National Health Service after reducing the price of the drug. The drug had failed to meet the National Health Service's cost-benefit profile last October. Takeda revised its proposal by adding a price-reduction scheme that would make the drug free for the first seven doses.

No comments:

Post a Comment